Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Drugs in Development, 2021
Summary Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) pipeline Target constitutes close to 6 molecules. The latest report Respiratory Syncytial Virus Attachment Glycoprotein - Drugs In Development, 2021, outlays comprehensive information on the Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - Respiratory syncytial virus G protein is a protein produced by respiratory syncytial virus. It attaches the virion to the host cell membrane by interacting with heparan sulfate. It interacts with host CX3CR1, the receptor for the CX3C chemokine fractalkine, to modulate the immune response and facilitate infection. Secreted glycoprotein G helps RSV escape antibody-dependent restriction of replication by acting as an antigen decoy and by modulating the activity of leukocytes bearing Fc gamma receptors. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 4 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Respiratory Syncytial Virus (RSV) Infections.
Furthermore, this report also reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the global therapeutic landscape for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) - The report reviews Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics and enlists all their major and minor projects - The report assesses Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) targeted therapeutics
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G)Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Our reports have been used by over 10K customers, including:
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Exportin 1 - Drugs In Development, 2022’; Exportin 1 (Chromosome...
New Drug Approvals and Their Contract Manufacture - 2022 Edition Summary This report is the 12th edition of our long running analysis of the CMO Industry, using NDA approvals as the primary indicator of performance.New Drug Approvals and Their Contract Manufacture (formerly called CMO Scorecard)...
The global liquid handling systems market is expected to reach USD 5.1 billion by 2026 from USD 4.0 billion in 2021, at a CAGR of 5.1% during the forecast period. The growth of this market is majorly driven by industrial growth in the pharma-biotech sector, rising R&D expenditure by biopharma companies, and growing life science research, supported...
The global precision medicine market reached a value of US$ 61.0 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 112.8 Billion by 2027, exhibiting at a CAGR of 10.1% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence...
Introduction to Compounded Resins Markets in 2022 The global Compounded Resins market is one of the high potential growth markets in the chemicals and materials industry, with a robust market size outlook and significant unmet opportunities for companies. The Compounded Resins market report is a comprehensive study on...
Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hyperalgesia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an...
175 pages •
By The Business Research Company
• Feb 2022
Major players in the cell based assays market are Thermo Fisher, Danaher , Becton, Dickinson and Company, GE Healthcare, Merck , Perkinelmer, Promega , Lonza, Charles River Laboratories and Cell Signaling Technology. The global cell based assays market is expected to grow from $20.73 billion in 2021 to $22.58 billion in 2022 at a compound...
Global In-Silico Drug Discovery Market to Reach $6,515.3 Million by 2031 Market Report Coverage - In-Silico Drug Discovery Market Segmentation • Workflow - Discovery, Pre-Clinical Tests, and Clinical Trials • Products - Software, Software-as-a-Service (SaaS), and Consultancy-as-a-Service •...
The global IVD contract research organization market is expected to grow from US$ 4,738.79 million in 2021 to US$ 8,019.53 million by 2028; it is estimated to grow at a CAGR of 7.8% from 2021 to 2028. The rising prevalence of infectious diseases increases the demand for IVD and clinical trials along with new product launches, which...
The global ATP assays market is projected to reach USD 412 million by 2027 from USD 276 million in 2022, at a CAGR of 8.4%. The growth of this market can largely be attributed to the increasing food safety concerns, growing demand for ATP assays in pharmaceutical & biotechnology companies, rising investments in pharmaceutical & biotechnology...
Pharmaceutical R&D Expenditure
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.